dipyridamole has been researched along with Hepatitis C, Chronic in 4 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Hepatitis C, Chronic: INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hemolysis is a frequent adverse effect of ribavirin (RBV)." | 9.11 | Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C. ( Bihl, F; Grattagliano, I; Jüni, P; Lauterburg, BH; Palasciano, G; Palmieri, VO; Portincasa, P; Russmann, S, 2004) |
| "Hemolysis is a frequent adverse effect of ribavirin (RBV)." | 5.11 | Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C. ( Bihl, F; Grattagliano, I; Jüni, P; Lauterburg, BH; Palasciano, G; Palmieri, VO; Portincasa, P; Russmann, S, 2004) |
| "Today, treatment of chronic hepatitis C is based on a synergistic combination of pegylated interferon and ribavirin with antiprotease inhibitors." | 3.78 | A new tool to study ribavirin-induced haemolysis. ( Brochot, E; Capron, D; Castelain, S; Duchaussoy, I; Duverlie, G; François, C; Helle, F; Nguyen-Khac, E; Van Nhien, AN, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brochot, E | 1 |
| François, C | 1 |
| Castelain, S | 1 |
| Helle, F | 1 |
| Van Nhien, AN | 1 |
| Duchaussoy, I | 1 |
| Capron, D | 1 |
| Nguyen-Khac, E | 1 |
| Duverlie, G | 1 |
| Grattagliano, I | 1 |
| Russmann, S | 1 |
| Palmieri, VO | 1 |
| Jüni, P | 1 |
| Bihl, F | 1 |
| Portincasa, P | 1 |
| Palasciano, G | 1 |
| Lauterburg, BH | 1 |
| Iagoda, AV | 1 |
| Koroĭ, PV | 1 |
| Horino, T | 1 |
| Kuriyama, S | 1 |
| Tomonari, H | 1 |
| Numata, M | 1 |
| Hayashi, F | 1 |
| Nagata, H | 1 |
| Hikita, M | 1 |
| Utsunomiya, Y | 1 |
| Kawamura, T | 1 |
| Hosoya, T | 1 |
1 trial available for dipyridamole and Hepatitis C, Chronic
| Article | Year |
|---|---|
Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C.
Topics: Adult; Antiviral Agents; Cell Membrane; Dipyridamole; Erythrocytes; Female; Glutathione; Glutathione | 2004 |
3 other studies available for dipyridamole and Hepatitis C, Chronic
| Article | Year |
|---|---|
A new tool to study ribavirin-induced haemolysis.
Topics: Adenosine Triphosphate; Adult; Anemia, Hemolytic; Dipyridamole; Drug Evaluation, Preclinical; Drug T | 2012 |
[Thrombocytic dysfunctions and potentialities of their differential correction in chronic viral hepatitis].
Topics: Adolescent; Adult; Antiviral Agents; Blood Platelets; Chronic Disease; Dipyridamole; Female; Hepatit | 2004 |
[Renal damage in a chronic active hepatitis C patient receiving interferon-alpha therapy].
Topics: Aged; Anticoagulants; Antiviral Agents; Dipyridamole; Glomerulonephritis, Membranous; Heparin; Hepat | 1998 |